The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

Event outline

Interactive workshop with participants from academia, industry, and the regulators exploring the opportunities and challenges in tumour agnostic cancer drug development.
Sessions will discuss the successes and failures of previous trials in this area, explore trial design, and discuss biomarker development for patient stratification.

 

LEARNING OBJECTIVES
  • To understand the current landscape of tumour agnostic drug development
  • To be able to discuss suitable trial designs to deliver such studies
  • To develop an understanding of biomarker development and the need for agnostic tumour registrations
  • To understand the regulatory environment around these registrations

 

TARGET AUDIENCE

The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA, National Agencies), the pharmaceutical industry, HTAs, and patient advocates.

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

info@cddf.org
Tel: +32 2 880 62 70